Rinvoq vs Skyrizi for Crohn's: Pills, Injections and Evidence

Comparing Rinvoq vs Skyrizi for Crohn's disease starts with your treatment history and the routine you could manage. Rinvoq is an oral Janus kinase inhibitor, or JAK inhibitor, while Skyrizi is an injectable biologic targeting interleukin-23, according to their Rinvoq and Skyrizi prescribing information. Here is a framework for discussing both options with your gastroenterologist.

Rinvoq and Skyrizi treatment routines

Both treatments have an initial induction phase followed by maintenance treatment, described in the FDA Rinvoq overview and Skyrizi label. For a first comparison, put the scheduled treatments on a calendar and consider how each would fit around work, travel and your preferences about injections. Ask the team to show you the exact prescription and device before making plans around a particular routine.

Treatment	Adult Crohn's induction	Maintenance
Rinvoq	45 mg orally daily for 12 weeks	15 mg daily; 30 mg may be considered for refractory, severe or extensive disease
Skyrizi	600 mg intravenously at weeks 0, 4 and 8	180 mg or 360 mg under the skin at week 12, then every eight weeks

Use this table to organize questions about the proposed regimen. Ask who will explain administration, arrange appointments and answer a question between visits. Request written instructions for your own prescription.

Why previous treatments matter

Rinvoq's US Crohn's indication includes inadequate response or intolerance to a tumor necrosis factor blocker; when those medicines are clinically inadvisable, the label requires previous use of at least one approved systemic therapy, according to Current US eligibility language.

The American Gastroenterological Association, or AGA, groups treatments differently depending on previous advanced-therapy exposure: its Crohn's guideline places risankizumab among higher-efficacy choices in both settings, while upadacitinib is in that group after previous advanced therapy, according to AGA Crohn's treatment guidance.

Ask your gastroenterologist to connect that evidence to your own history. For every previous medicine, write down whether it never helped, helped and then stopped, caused a problem, or was discontinued for another reason. Include approximate dates if you have them. A useful question is: “Which part of my treatment history makes you favor Rinvoq or Skyrizi now?” Leave room beside the answer for anything you want explained again.

Reading the effectiveness evidence

The FDA's review of the Rinvoq Crohn's program found better clinical remission and intestinal-inflammation outcomes with treatment than placebo during induction, with maintenance benefit assessed among initial responders, according to FDA assessment of the Crohn's trials.

Skyrizi's ADVANCE and MOTIVATE induction studies also compared treatment with placebo; the label reports clinical remission and endoscopic-response outcomes at week 12, followed by a responder-based maintenance study, according to Skyrizi Crohn's study results.

Those are separate study programs with their own populations and comparison groups, so their headline percentages alone do not establish which medicine would work better for you. This is a limitation of comparing the Rinvoq study design with the Skyrizi study design.

When someone quotes a success rate, ask which outcome it describes, when it was measured and which patients were included. Request the original study or prescribing-information section so you can revisit the explanation. Keep the treatment recommendation separate from any assumption that one trial percentage is your personal probability of success.

Safety and monitoring deserve their own discussion

Rinvoq carries boxed warnings concerning serious risks, including cardiovascular events, cancer, blood clots and death; the FDA's class-warning decision drew on a tofacitinib safety trial in rheumatoid arthritis, according to FDA explanation of the JAK warnings.

The FDA advises discussing smoking history and previous cardiovascular events or blood clots with the prescriber, according to Risk factors to discuss before treatment.

Skyrizi's precautions include infection and tuberculosis assessment, plus liver-enzyme and bilirubin monitoring before treatment and through at least the first 12 weeks of induction, according to Skyrizi screening and liver precautions.

Ask which risks are most relevant to your history, what testing is planned and who will review the results. Request clear instructions for contacting the team about a new symptom. If a warning worries you, bring the exact wording to the appointment and ask for an explanation in your clinical context.

An appointment worksheet for the decision

Prepare one page with the names and dates of previous treatments at the top. Beneath that, describe what you most want the next treatment to help you accomplish in daily life. Be specific about your priorities, such as attending work reliably or feeling comfortable with the administration routine.

Use the remaining space for questions: What is the reason for recommending this option? What will we measure at follow-up? Who should I contact if there is a prescription or scheduling problem? If the recommendation changes, what information led to that change?

Before leaving, ask for the agreed next step, the planned review date and a contact route in writing. You do not need to resolve every uncertainty in one conversation. Record what has been decided and what still needs an answer, then bring that same page to the follow-up discussion.